Physician Education: Bridging Clinical Research and Patient Care

Faculty Profile

Topics of Professional Interest:
  • New agents and therapeutic strategies for HIV infection
  • When to start, when to swtich, and when to stop therapy
  • Interactions between tuberculosis and HIV in coinfected patients
Current Professional Summary:

Dr Havlir is a Professor of Medicine at University of California San Francisco. She directed the UCSD Treatment Center, a clinical research center dedicated to evaluating new therapies for the treatment of HIV disease and associated complications. Her research interests included developing and testing new agents and therapeutic strategies for HIV-infected, treatment-naive and -experienced patients. When to start, when to switch, and when to stop therapy remain fundamental questions in the management of HIV-infected patients. She was also studying the interactions between tuberculosis and HIV in patients coinfected with these two pathogens.

Committees and Organizations:
  • President, Association of Women Students, St Olaf College (1979–1980)
  • President, American Medical Women's Association, Duke University (1983–1984)
  • Internship Selection Committee, University of California San Francisco (1987–1988)
  • Internship Selection Committee, University of California, San Diego (1991–)
  • Committee on Academic Promotions, University of California San Diego (1997–)
Honors and Awards:
  • Phi Beta Kappa, St Olaf College
  • Alpha Omega Alpha, Duke University Medical School
  • Merck Community Service Award
  • Medical Student Fellowship, National Council on Aging
  • Duke University School of Medicine, MD (1984)
  • University of California San Francisco, Residency in Internal Medicine, (1984–1987)
  • University Hospitals, Cleveland, OH, Infectious Diseases Fellowship (1988–1990)
Selected Publications:
  1. Zhang Z-Q, Schuler T, Zupancic M, Wietgrefe S, Staskus KA, Reimann KA, Reinhart TA, Rogan M, Cavert W, Miller CJ, Veazy RS, Notermans D, Little S, Danner SA, Richman DD, Havlier D, Wong J, Jordan HL, Schacker TW, Racz P, Tenner-Racz K, Letvin NL, Wolinsky S, Haase AT. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science. 1999;286:1353-1357.
  2. Havlir DV, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, Tebas P, Sommadossi JP, Richman DD. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA. 2000;283:229-234.
  3. Schacker T, Little S, Conncik E, Gebhard-Mitchell K, Zhang Z-Q, Krieger J, Pryor J, Havlir D, Wong JK, Richman D, Corey L, Haase AT. Rapid accumulation of human immunodeficiency virus (HIV) in lymphatic tissue reservoirs during acute and early HIV infection: implications for timing of antiretroviral therapy. J Infect Dis. 2000;181:354-357.
  4. Günthard HF, Wong JK, Spina CA, Ignacio C, Kwok S, Christopherson C, Hwang J, Haubrich R, Havlir D, Richman DD. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis. 2000;181:522-531.
  5. O'Brien TR, McDermott DH, Ioannidis JPA, Carrington M, Murphy PM, Havlir DV, Richman DD. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS. 2000;14:821-826.
  6. Havlir DV, Tierney C, Friedland GH, Pollard RB, Smeaton L, Sommadossi J-P, Fox L, Kessler H, Fife KH, Richman DD. In vivo antagonism with zidovudine plus stavudine combination therapy. J Infectious Dis. 2000;182:321-325.
  7. Gulick RM, Mellors JW, Havlir DV, Eron JJ, Meibohm A, Condra JH, Valentine FT, McMahon D, Gonzalez C, Jonas L, Emini EA, Chodakewitz JA, Isaacs R, Richman DD. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med. 2000;133:35-39.
  8. Appay V, Nixon DF, Donahoe SM, Gillespie GM, Dong T, King A, Ogg GS, Spiegel HM, Conlon C, Spina CA, Havlir DV, Richam DD, Waters A, Easterbrook P, McMichael AJ, Rowland-Jones SL. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exper Med. 2000;192:63-75.
  9. Ioannidis JPA, Havlir DV, Tebas P, Hirsch MS, Collier AC, Richman DD. Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication. AIDS. 2000;14:1481-1488.
  10. Havlir DV, Schrier RD, Torriani FJ, Chervenak K, Hwang JY, Boom WH. Effect of potent antiretroviral therapy on immune responses to Mycobacterium avium in HIV-infected subjects. J Infect Dis. Accepted for publication.

TAM Articles